This study is open to adults with advanced colorectal cancer or with advanced pancreatic
cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a
medicine called BI 905711 combined with chemotherapy and bevacizumab. The purpose of the
first part is to find the highest BI 905711 dose participants can tolerate. In the second
part, participants with colorectal cancer or pancreatic cancer get BI 905711 combined with
chemotherapy. Some participants also get bevacizumab. The second part tests whether BI 905711
makes tumours shrink. Participants get BI 905711, chemotherapy and bevacizumab about every 2
weeks as an infusion into a vein. Participants can stay in the study as long as they benefit
from treatment and can tolerate it. The doctors regularly check the health of the
participants and note any health problems that could have been caused by the study treatment.
The doctors also monitor the size of the tumour.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.